stockrowDENTSPLY SIRONA Inc.
XRAY Healthcare Medical Instruments & Supplies
DENTSPLY SIRONA Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.7 billion, down 2.98% from fiscal 2024.
- Revenue
- −7.52%
- EPS
- +99.5%
- Free cash flow
- −18.0%
- Total debt
- −1.59%
Quarter to September 2026, against a year earlier
Follow XRAY
Alert me
DENTSPLY SIRONA Inc. (XRAY) EPS (diluted)
DENTSPLY SIRONA Inc.'s EPS (diluted) for fiscal 2025 was −$3.00, compared with −$4.48 in fiscal 2024. Over the twelve months to 30 September 2026 it was −$0.62. Over the past ten years it has ranged from −$6.86 (fiscal 2017) to $1.94 (fiscal 2016); the current reading is higher than 45% of that period. DENTSPLY SIRONA Inc. ranks 34th of 47 Medical Instruments & Supplies companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | −$3.00 | — |
| FY2024 | −$4.48 | — |
| FY2023 | −$0.62 | — |
| FY2022 | −$4.41 | — |
| FY2021 | $1.91 | — |
| FY2020 | −$0.38 | — |
| FY2019 | $1.17 | — |
| FY2018 | −$4.51 | — |
| FY2017 | −$6.86 | — |
| FY2016 | $1.94 | 10.23% |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Sep 2026 | −$0.01 | — |
| Jun 2026 | $0.18 | — |
| Mar 2026 | −$0.05 | — |
| Dec 2025 | −$0.74 | — |
| 43 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| LMAT LeMaitre Vascular, Inc. compare | $2.75 |
| STVN Stevanato Group S.p.A. compare | $0.59 |
| ATRC AtriCure, Inc. compare | $0.30 |
| WRBY Warby Parker Inc. compare | $0.06 |
| STAA STAAR Surgical Company compare | $0.00 |
| XRAY DENTSPLY SIRONA Inc. | −$0.62 |
| PLSE Pulse Biosciences, Inc compare | −$1.21 |
| AZTA Azenta, Inc. compare | −$2.67 |
| KMTS Kestra Medical Technologies, Ltd. compare | −$2.67 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on XRAY
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement